Magnolia engaged pharmacy directors, medical directors, and actuaries at health plans and PBMs to understand how payers are designing their plan offerings and adjusting their formularies in the coming years.
Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.
Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.
Download to see features of the new healthcare delivery model and value-based care payment system for oncology practices, administered by the Centers for Medicare and Medicaid Services (CMS).
To gather early perceptions of the EOM and understand how oncology practices evaluated participation decisions in the new model, Magnolia facilitated an advisory panel discussion with key opinion leaders.
Biopharmaceutical companies engaged Magnolia to help them understand the implications of the Inflation Reduction Act of 2022 and develop long-term strategic plans to adjust for the sweeping market changes it will cause.
A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies.
A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease.
Download to see features of the proposed rule.